Donepezil potentiates nerve growth factor-induced neurite outgrowth in PC12 cells

Journal of Pharmacological Sciences

Volumn 104, Issue 4, 2007, Pages 349-354

  Oda, Toru ^a   Kume, Toshiaki ^a   Katsuki, Hiroshi ^a   Niidome, Tetsuhiro ^a   Sugimoto, Hachiro ^a   Akaike, Akinori ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Donepezil; Extracellular signal regulated kinase (ERK); Nerve growth factor (NGF); Neurite outgrowth; PC12

Indexed keywords

BUCLADESINE; CARBACHOL; CHOLINERGIC RECEPTOR; DONEPEZIL; GALANTAMINE; MECAMYLAMINE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NICOTINE; PHYSOSTIGMINE; SCOPOLAMINE; TACRINE;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL STRAIN; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; IMMUNOBLOTTING; NERVE FIBER GROWTH; NONHUMAN; RAT;

EID: 34548495340     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0070563     Document Type: Article

References (16)

1. Yankner BA. A century of cognitive decline. Nature. 2000;404:125.
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;4:487-498.
3. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237-1239.
4. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403.
5. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem. 2000;74: 237-243.
6. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry. 2001;49:175-184.
7. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestation of Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17:100-108.
8. Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y. Donepezil hydrochloride (E2020) and other cholinesterase inhibitors. Curr Med Chem. 2000;7:303-339.
9. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther. 2003;306:772-777.
10. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology. 2006;51:474-486.
11. Keegan K, Halegoua S. Signal transduction pathways in neuronal differentiation. Curr Opin Neurobiol. 1993;3:14-19.
12. Gunning PW, Letourneau PC, Landreth GE, Shooter EM. The action of nerve growth factor and dibutyryl adenosine cyclic 3′:5′-monophosphate on rat pheochromocytoma reveals distinct stages in the mechanisms underlying neurite outgrowth. J Neurosci. 1981;1:1085-1095.
13. Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell. 1997;89:73-82.
14. Green LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A. 1976;73:2424-2428.
15. Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett. 1999;260:5-8.
16. Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther. 2002;303:1227-1237.